Synthetic Silvestrol Analogues as Potent and Selective Protein Synthesis Inhibitors
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Misregulation of protein translation plays a critical role in human cancer pathogenesis at many levels. Silvestrol, a cyclopenta[b]benzofuran natural product, blocks translation at the initiation step by interfering with assembly of the eIF4F translation complex. Silvestrol has a complex chemical structure whose functional group requirements have not been systematically investigated. Moreover, silvestrol has limited development potential due to poor druglike properties. Herein, we sought to develop a practical synthesis of key intermediates of silvestrol and explore structure-activity relationships around the C6 position. The ability of silvestrol and analogues to selectively inhibit the translation of proteins with high requirement on the translation-initiation machinery (i.e., complex 5'-untranslated region UTR) relative to simple 5'UTR was determined by a cellular reporter assay. Simplified analogues of silvestrol such as compounds 74 and 76 were shown to have similar cytotoxic potency and better ADME characteristics relative to those of silvestrol.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yang, H.-S., Jansen, A. P., Komar, A. A., Zheng, X., Merrick, W. C., Costes, S., Lockett, S. J., Sonenberg, N., & Colburn, N. H. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.1.26-37.2003 · Cited by 494
She, Q.-B., Halilovic, E., Ye, Q., Zhen, W., Shirasawa, S., Sasazuki, T., Solit, D. B., & Rosen, N. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.023 · Cited by 400
Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol
Cencic, R., Carrier, M., Galicia-Vázquez, G., Bordeleau, M.-E., Sukarieh, R., Bourdeau, A., Brem, B., Teodoro, J. G., Greger, H., Tremblay, M. L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005223 · Cited by 302
Self-citationJansen, A. P., Camalier, C. E., Stark, C., & Colburn, N. H. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.103.3.2 · Cited by 132
Rodrigo, C. M., Cencic, R., Roche, S. P., Pelletier, J., & Porco, J. A. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201263k · Cited by 99
Gupta, S. V., Sass, E. J., Davis, M. E., Edwards, R. B., Lozanski, G., Heerema, N. A., Lehman, A., Zhang, X., Jarjoura, D., Byrd, J. C., et al. (2011) · The AAPS Journal · doi:10.1208/s12248-011-9276-7 · Cited by 81
Cited by
Targeting the translation machinery in cancer
Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4505 · Cited by 799
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies
Boussemart, L., Malka-Mahieu, H., Girault, I., Allard, D., Hemmingsson, O., Tomasic, G., Thomas, M., Basmadjian, C., Ribeiro, N., Thuaud, F., et al. (2014) · Nature · doi:10.1038/nature13572 · Cited by 371
Targeting the eIF4F Translation Initiation Complex: A Critical Nexus for Cancer Development
Pelletier, J., Graff, J., Ruggero, D., & Sonenberg, N. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2789 · Cited by 367
“A current barrier to the clinical development of silvestrol is that resistance can develop due to overexpression of the ABCB1/P-glycoprotein (186, 189).”
BackgroundRocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor
Iwasaki, S., Floor, S. N., & Ingolia, N. T. (2016) · Nature · doi:10.1038/nature17978 · Cited by 313
Ernst, J. T., Thompson, P. A., Nilewski, C., Sprengeler, P. A., Sperry, S., Packard, G., Michels, T., Xiang, A., Tran, C., Wegerski, C. J., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00182 · Cited by 150
Metadata
- Authors
- Liu, T., Nair, S. J., Lescarbeau, A., Belani, J., Peluso, S., Conley, J., Tillotson, B., O’Hearn, P., Smith, S., Slocum, K., West, K., Helble, J., Douglas, M., Bahadoor, A., Ali, J., McGovern, K., Fritz, C., Palombella, V. J., Wylie, A., Castro, A. C., & Tremblay, M. R.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2012-10-12
- Volume
- 55
- Issue
- 20
- Pages
- 8859-8878
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2082954801
- Cited by
- 84
- References
- 6
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Synthetic Silvestrol Analogues as Potent and Selective Protein Synthesis Inhibitors. https://app.cochat.ai/papers/10.1021/jm3011542
- The paper
- Liu, T., Nair, S. J., Lescarbeau, A., Belani, J., Peluso, S., Conley, J., Tillotson, B., O’Hearn, P., Smith, S., Slocum, K., West, K., Helble, J., Douglas, M., Bahadoor, A., Ali, J., McGovern, K., Fritz, C., Palombella, V. J., Wylie, A., . . . Tremblay, M. R. (2012). Synthetic Silvestrol Analogues as Potent and Selective Protein Synthesis Inhibitors. Journal of Medicinal Chemistry. https://doi.org/10.1021/jm3011542
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.